dipyridamole has been researched along with Cardiac Conduction Defect in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DEMIROGLU, C | 1 |
| BERKARDA, B | 1 |
| OZTUERK, M | 1 |
| GARAN, R | 1 |
| CHROBOK, H | 1 |
2 other studies available for dipyridamole and Cardiac Conduction Defect
| Article | Year |
|---|---|
[ON AN INTERESTING ACTION OF PERSANTIN ON HEART CONDUCTION DISORDERS].
Topics: Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Dipyridamole; Electrocard | 1964 |
[3 CASES OF TRANSIENT BUNDLE BRANCH BLOCK].
Topics: Bundle-Branch Block; Cardiac Conduction System Disease; Dipyridamole; Drug Therapy; Heart Block; Hum | 1965 |